Genomic medicine for non-surgical lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is part of a lung cancer network that uses genetic (DNA) testing to better understand and treat non-surgical lung cancer. You might be eligible if you have certain stages of non-small cell lung cancer and can consent to participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have non-small cell lung cancer confirmed by tissue biopsy (histology)
- Have lung cancer that is stage IIIb or stage IV and cannot be removed with surgery
- Or, from July 2023 onward: have stage Ib, II, or III lung cancer
- Be able to provide written informed consent (sign the consent form)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic changes in people with suspected or high-risk lung cancer. It aims to use those results to guide more personalized treatment decisions.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This trial studies a “cell-free DNA” blood test to help diagnose and guide treatment decisions for early non-small cell lung cancer. It may help doctors tailor care based on genetic signals seen in the blood before and around surgery.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.